Sciendio turns public epidemiological data into case forecasts and market-size estimates for rare diseases. Type in an indication, get a data-backed number in minutes — enough to judge whether an investment is worth pursuing, before you spend on a full market report.
The data needed to size a rare disease opportunity exists — it's just scattered, expensive, and priced for companies that have already decided to commit.
Prevalence figures, treatment landscapes and patient population estimates are spread across registries, journals and proprietary databases that rarely talk to each other — hard to pull together for a quick internal check.
A single market report from a traditional research firm can run into five figures — a hard sell when you're still trying to find out whether the opportunity is worth pursuing in the first place.
When a first market read takes weeks and a big budget, smaller teams and startups without deep pockets end up skipping the analysis — and sometimes the opportunity — entirely.
Anyone who wants to know how case numbers for a rare hereditary disease like hemophilia will develop today has two options: a rough linear projection based on outdated incidence rates — or five-figure sums for exclusive market research reports from major providers. For business development teams, corporate strategy, and startups without a research budget, neither is good enough. Sciendio closes this gap: we process freely available raw data into precise, on-demand forecasts of future case numbers and market sizes — enough to take into a decision meeting, before you commission the full report.
Instead of relying on rigid, linear extrapolations, our platform processes publicly available raw data through a custom-built Monte Carlo simulation. It models thousands of potential future scenarios to deliver reliable probability distributions you can use to size the opportunity — and to show your confidence interval, not just a single number.
The underlying algorithm is specifically tailored to hereditary diseases, factoring in complex shifting variables such as regional demographic trends and rising life expectancy driven by modern therapeutics — the kind of detail that a rough back-of-envelope estimate misses.
Select a disease category to simulate future case numbers and market size.
An inherited bleeding disorder in which the blood does not clot properly due to lack of coagulation factors.
Run the simulation above to calculate multi-scenario forecasting models.
Faster access to the numbers doesn't just save time — it changes which decisions get made at all.
Feasibility checks and opportunity assessments that used to take weeks of manual digging can take hours — enough to walk into a leadership or board discussion with real numbers, not a gut feeling.
A fast, low-cost first estimate lets you rule opportunities in or out before committing to a full commercial due-diligence report — so the expensive research only gets ordered once it's actually justified.
When a solid market estimate isn't gated by a big research budget, startups and lean teams can evaluate the same opportunities as larger, better-funded competitors.
We want to build this platform around how business development, strategy and investment teams actually work. Tell us which decisions you need faster market sizing for, how you currently work around the lack of it, and what would make this a tool you reach for before every go/no-go call.
FeedbackTakes about 1 minute · no payment, no commitment